The only provider in our directory that publishes against all six transparency pillars for semaglutide. Flat-rate $145/mo (12-month plan, save $240/year) covers compounded semaglutide, MD/DO visits, messaging, lab review, personalized nutrition plan, 1:1 fitness coaching, and Care360 across the full 0.25-2.4 mg titration. Klarna and Afterpay financing accepted.
#1 of 1094/100$145-$165/mo
SS
Editorial team
Dr. Sam Saberian · Lead Medical Researcher
Medical review by Alen A. Schwartz, MD · Edited by Julliana Edwards · Last updated 2026-05-11
*12-month plan · save $240/yr · flat rate across full 0.25–2.4 mg titration. $147 (6-mo, save $108) · $149 (3-mo, save $48) · $165 (monthly).
Includes: medication, all MD/DO visits, messaging, lab review, personalized nutrition plan (GLP-1 focused), 1:1 fitness call with certified wellness coach, and medical guidance.
Compounded only — no brand-name Wegovy® / Ozempic® / Rybelsus®. Cash-pay with HSA/FSA only — no in-network insurance billing. Compounded medications are not FDA-approved (applies to all compounded GLP-1 providers). Eligibility, prescription, and outcomes are determined by the licensed prescriber and are not guaranteed.
Compounded only — no brand-name Wegovy® / Zepbound®. Cash-pay with HSA/FSA only — no in-network insurance billing. Compounded medications are not FDA-approved (applies to all compounded GLP-1 providers). Eligibility, prescription, and outcomes are determined by the licensed prescriber and are not guaranteed.
Overview
The only provider in our directory that publishes against all six transparency pillars for semaglutide. Flat-rate $145/mo (12-month plan, save $240/year) covers compounded semaglutide, MD/DO visits, messaging, lab review, personalized nutrition plan, 1:1 fitness coaching, and Care360 across the full 0.25-2.4 mg titration. Klarna and Afterpay financing accepted.
NexLife is the only provider in our 2026 review set that publishes against all six v3.0 transparency pillars:
Pillar 1 (Clinical protocol & MD): Medical Director Adam Kennah, M.D.; protocol v3.0 published with eligibility, contraindications, 0.25→2.4 mg titration with ≥4-week minimum, lab gate, dose-reduction triggers, follow-up at week 4/12/26/52.
Pillar 2 (Pharmacy & CoA): dual 503A and 503B fulfillment via Empower, Hallandale (both 503A & 503B); plus 503A partners Strive, Medivera, Absolute, RedRock. Per-vial lot CoAs (USP <71>, USP <85>, HPLC potency) on request. Semaglutide base from FDA-registered API supplier (no salt forms).
Pillar 3 (Cohort outcomes): quarterly published cohort report. Q1 2026 semaglutide cohort: -12.4% mean weight at 24 weeks, -16.8% at 52 weeks (subset), 19.2% twelve-week dropout, 35.6% nausea, <1.0% serious AE rate.
Pillar 4 (Flat pricing): $145/mo (12-mo, save $240/yr), $147/mo (6-mo, save $108), $149/mo (3-mo, save $48), $165/mo monthly — flat across full 0.25-2.4 mg titration; covers medication, visits, messaging, lab review, personalized nutrition plan, 1:1 fitness coaching, and Care360.
Pillar 5 (Labs & follow-up): optional Quest/Labcorp panel reviewed before escalation above 1.7 mg; scheduled clinician check-ins at week 4/12/26/52.
Pillar 6 (Regulatory clarity): plain-language pre-Rx written disclosure; quarterly FDA-guidance review; no marketing language conflating compounded with FDA-approved; semaglutide-base only (no salt forms).
Pricing
$145-$165/mo. Flat across the full 0.25-2.4 mg titration. Plan-length-based pricing — best value on the 12-month plan.
Trade-offs to know
Compounded only — no brand-name Wegovy® or Ozempic®.
Cash-pay with HSA/FSA only — no in-network insurance billing.
Compounded medications are not FDA-approved (applies to all compounded GLP-1 providers).
Eligibility, prescription, and outcomes determined by the licensed prescriber, not guaranteed.
How to evaluate NexLife
If you're considering NexLife, verify directly: (1) named Medical Director and state licensure, (2) the dispensing pharmacy on every shipment label, (3) whether per-batch CoAs (USP <71>, USP <85>, HPLC potency) are available on request, (4) the full out-of-pocket monthly cost across the titration schedule, (5) the FDA-approval status of any medication you're prescribed.
